Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30774901 | 0.84 | RORC (0.40) | NR1H2USP2SMN1; SMN2ESR2DDB1 | |
| SCHEMBL29440339 | 0.83 | USP2 (0.41) | NR1H2USP2SMN1; SMN2ESR2DDB1 | |
| SCHEMBL517374 | 0.83 | NR1H2 (0.46) | NR1H2USP2SMN1; SMN2ESR2DDB1 | |
| SCHEMBL27143468 | 0.81 | EPHX2 (0.39) | NR1H2USP2SMN1; SMN2ESR2DDB1 | |
| SCHEMBL29116107 | 0.81 | USP30 (0.46) | NR1H2USP2SMN1; SMN2ESR2DDB1 | |
| SCHEMBL27660306 | 0.80 | NR1H2 (0.44) | NR1H2USP2SMN1; SMN2ESR2DDB1 | |
| Iodomethane SCHEMBL3387530 | 0.80 | NR1H2 (0.44) | NR1H2USP2SMN1; SMN2ESR2DDB1 | |
| SCHEMBL12129003 | 0.79 | NR1H2 (0.43) | NR1H2USP2SMN1; SMN2ESR2DDB1 | |
| SCHEMBL29915399 | 0.78 | NR1H2 (0.42) | NR1H2USP2SMN1; SMN2ESR2DDB1 | |
| SCHEMBL29614642 | 0.77 | NR1H2 (0.41) | NR1H2USP2SMN1; SMN2ESR2DDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4313295-A1 | PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | Almac Discovery Limited (GB) | 2024-02-07 | — | — | EP | disclosed |
| CN-117157285-A | Pharmaceutical compounds as ubiquitin-specific protease 19 (USP 19) inhibitors | 阿尔麦克探索有限公司 | 2023-12-01 | — | — | CN | disclosed |
| US-20230109839-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | Sumitomo Pharma Co., Ltd. (JP) | 2023-04-13 | — | — | US | disclosed |
| WO-2022200523-A9 | PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | ALMAC DISCOVERY LIMITED (GB) | 2023-02-16 | — | — | WO | disclosed |
| EP-4104861-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | Sumitomo Pharma Co., Ltd. (JP) | 2022-12-21 | — | — | EP | disclosed |
| CN-115397467-A | Therapeutic agent for tauopathy | 住友制药株式会社 | 2022-11-25 | — | — | CN | disclosed |
| US-20220347175-A1 | PYRIDAZINONE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-11-03 | — | — | US | disclosed |
| WO-2022200523-A1 | PHARMACEUTICALS COMPOUNDS AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | ALMAC DISCOVERY LIMITED (GB) | 2022-09-29 | — | — | WO | disclosed |
| CN-114206872-A | Imidazo [2,1-F ] [1,2,4] triazin-4-amine derivatives as TLR8 agonists | 百济神州有限公司 | 2022-03-18 | — | — | CN | disclosed |
| EP-3828174-A1 | PYRIDAZINONE DERIVATIVE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2021-06-02 | — | — | EP | disclosed |
| CN-112672997-A | Pyridazinone derivatives | 大日本住友制药株式会社 | 2021-04-16 | — | — | CN | disclosed |
| CN-112321590-A | Imidazo [2,1-F ] [1,2,4] triazin-4-amine derivatives as TLR8 agonists | 百济神州有限公司 | 2021-02-05 | — | — | CN | disclosed |
| WO-2020017587-A1 | PYRIDAZINONE DERIVATIVE | 大日本住友製薬株式会社 | 2020-01-23 | — | — | WO | disclosed |
| WO-2018089904-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | 3-V BIOSCIENCES, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220347175-A1 | PYRIDAZINONE DERIVATIVE | SCN1A, SCN1B, SCN3A | NR1H2 437/4885USP2 4433/4885SMN1; SMN2 86/4885 |
| US-20230109839-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | MAPT, PSEN1, PSEN2 | NR1H2 1860/4885USP2 3851/4885SMN1; SMN2 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.